Wells Fargo lowered the firm’s price target on Viridian Therapeutics (VRDN) to $26 from $27 and keeps an Equal Weight rating on the shares. The firm thinks shares will remain range bound in the near term ahead of key catalysts in 2026, and sees little upside on VRDN-006 Phase 1 data in Q3 2025. That said, management continues to execute well and reiterated key timelines for veligrotug and VRDN-003, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments
- Viridian Therapeutics Reports Q2 2025 Financial Results
- Viridian Therapeutics: Promising Outlook with Positive Phase 3 Data and Strategic Licensing Agreements
- Viridian Therapeutics: Strong Financial Position and Promising Pipeline Support Buy Rating
- Viridian Therapeutics: Promising Future with Strong Financials and Strategic Developments